Responsible Lobbying Harvard Case Solution & Analysis

In 2006, Merck received FDA approval for Gardasil, the first vaccine for human papillomavirus (HPV), which has been identified as the cause of cervical cancer. Merck vaccine price of $ 360 for three shots and working on the programs for Gardasil in developing countries at lower prices. Projected Gardasil sales of $ 1 billion a year and billions more if the state ordered the vaccination. Prior to approval of FDA, Merck began to develop market Gardasil and launched an intensive campaign to get the state to make the HPV vaccine for girls entering middle school compulsory. Public and private organized groups became aware of efforts Merck, however, the campaign generated a backlash against mandatory vaccination. Merck subsequently suspended his campaign and reflect on their experience in dealing with the next turn. "Hide
by David P. Baron Source: Stanford Graduate School of Business 10 pages. Publication Date: August 5, 2008. Prod. #: P57-PDF-ENG

Responsible Lobbying Case Solution Other Similar Case Solutions like

Responsible Lobbying

Share This